Skip to main content

Table 2 Univariate and multivariate analysis of HOXD10 methylation status with 3-year overall survival (OS) in HCC patients

From: Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma

Clinical factor

3-year OS

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Age (< 60 vs. ≥ 60 years)

1.306 (0.775–2.201)

0.317

  

Gender (male vs. female)

0.717 (0.376–1.368)

0.312

  

HOXD10 (methylation vs. unmethylation)

1.920 (1.006–3.664)

0.048*

1.676 (0.864–3.252)

0.127

HBV infection (yes vs. no)

0.664 (0.374–1.178)

0.161

  

Liver cirrhosis (yes vs. no)

0.888 (0.513–1.538)

0.672

  

Tumor size (≤ 5 vs. > 5 cm)

0.707 (0.412–1.212)

0.207

  

Number of lesions (1 vs. ≥ 1)

0.770 (0.439–1.349)

0.361

  

Differentiation (well or moderate vs. poor)

0.787 (0.476–1.301)

0.351

1.267 (0.740–2.172)

0.388

TNM stage (stage I + stage II vs. stage III + stage IV)

0.391 (0.233–0.656)

0.000***

0.502 (0.279–0.902)

0.021*

Lymph node metastasis (negative vs. positive)

0.431 (0.172–1.075)

0.071

  

Vessel cancerous embolus (negative vs. positive)

0.356 (0.217–0.584)

0.000***

0.503 (0.287–0.884)

0.017*

  1. *P < 0.05, ***P < 0.001